| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Avidity Biosciences, Inc. (RNA) has 13 insiders with recent SEC Form 4 filings, including 0 buys and 11 sells. RNA is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 283.4K | $3.67M | - | |
| Other | 205.0K | $2.65M | - | |
| Other | 116.9K | $1.51M | - | |
| Other | 91.6K | $1.19M | - | |
| Other | 79.0K | $1.02M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jun 4, 2024 | Boyce Sarah | President And CEO | Sale+OE | 28,000 | $27.42 | $767,779.60 | -20.0% | |
| May 20, 2024 | Levin Arthur A | Director | Sale+OE | 5,000 | $29.90 | $149,481.00 | -25.2% | |
| May 14, 2024 | MacLean Michael F | Chief Financial Officer | Sale+OE | 75,000 | $28.28 | $2,121,045.00 | -63.0% | |
| May 7, 2024 | Boyce Sarah | President And CEO | Sale+OE | 28,000 | $25.54 | $715,050.00 | -20.0% | |
| Apr 19, 2024 | Levin Arthur A | Director | Sale+OE | 5,000 | $22.82 | $114,123.00 | -25.2% | |
| Apr 3, 2024 | Levin Arthur A | Director | Sell | 20,000 | $27.11 | $542,214.00 | -7.3% | |
| Apr 2, 2024 | Boyce Sarah | President And CEO | Sale+OE | 28,000 | $26.25 | $734,918.80 | -20.0% | |
| Mar 19, 2024 | Levin Arthur A | Director | Sale+OE | 5,000 | $23.97 | $119,847.50 | -25.2% | |
| Mar 13, 2024 | MacLean Michael F | Chief Financial Officer | Sale+OE | 40,000 | $24.52 | $980,760.00 | -47.6% | |
| Mar 12, 2024 | Levin Arthur A | Director | Sale+OE | 27,641 | $22.03 | $609,017.00 | -46.1% |